Medical Radiology and Radiation Safety. 2015. Vol. 60. No. 1. P. 54-61

RADIATION PHYSICS, TECHNOLOGY AND DOSIMETRY

L.Ya. Klepper

Formation Optimum Doses Fields in Interstitial Radiotherapy as the Problem of the Covering of the Target by Circles of Identical Radius

Central Economic Mathematical Institute of RAS, Moscow, Russia, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. This email address is being protected from spambots. You need JavaScript enabled to view it.

ABSTRACT

The purpose of work consists in description of the problem of optimum sources accommodation in a target at interstitial radiotherapy of malignant tumor by methods of the «Parisian grid» and methods of optimum sources accommodation which are reduced to problems of an optimum covering of a target by identical circles of the minimal radius. Connection between two methods is tracked. It is shown, that particular decisions can be equivalent to the «Parisian grid» method. Examples of the problem decision and the analysis of the decisions received are presented.

Key words: interstitial radiotherapy, optimum distribution of intrastats

REFERENCES

1. Pavlov A.S. Vnutritkanevaya gamma i betaterapiya zlokachestvennykh opukholei. Moscow, Meditsina. 1967. 234 p.
2. Ivanov V.I. Kurs dozimetrii. Moscow: Energoatomizdat. 1988. 399 p..
3. Klepper L.Ya. Formirovanie dozovykh polei radioaktivnymi preparatami i applikatorami. Moscow: Energoatomizdat. 1986. 183 p.
4. Klepper L.Ya. Formirovanie optimal'nykh dozovykh polei v kontaktnoi luchevoi terapii zlokachestvennykh opukholei. Med. tekhnika. 2003. No. 2. P. 38-44.
5. Klepper L.Ya. Formirovanie optimal'nykh dozovykh polei na otrezke s pomoshch'yu tochechnykh i lineinykh istochnikov izlucheniya. Med. tekhnika. 2003. No. 4. P. 22-26.
6. Klepper L.Ya., Ushkova V.L., Rybina T.V. Optimizatsiya planov oblucheniya v kontaktnykh metodakh luchevoi terapii zlokachestvennykh opukholei s pomoshch'yu radiatsionnogo kompleksa «AGAT-VT». Med. fizika. 2002. No. 4. P. 27-40.
7. Klepper L.Ya. Metod interaktivnoi vizual'noi optimizatsii terapevticheskogo dozovogo polya v kontaktnoi luchevoi terapii zlokachestvennykh opukholei. Med. tekhnika. 2003. No. 5. P. 27-32.
8. Klepper L.Ya., Ushkova V.L. Uskorennyi metod opredeleniya optimal'nykh planov vnutritkanevoi luchevoi terapii zlokachestvennykh opukholei s pomoshch'yu PK «KONTAKT». Med. fizika. 2004. No. 3. P. 9-15.
9. Klepper L.Ya. Metod «kvazi-podobnykh mishenei» dlya formirovaniya effektivnykh terapevticheskikh dozovykh polei pri vnutritkanevoi luchevoi terapii zlokachestvennykh opukholei. Med. fizika. 2009. No. 1. P. 21-30.
10. Klepper L.Ya., Ushkova V.L. Optimal'noe raspredeleniya sistemy parallel'nykh intrastatov pri vnutritkanevoi luchevoi terapii (svoistvo kvazi-invariantnosti). Med. fizika. 2011. No. 3. P. 5-13.
11. Klepper L.Ya., Ushkova V.L. Formirovanie dopustimykh i dopustimo-optimal'nykh dozovykh polei dlya vnutritkanevoi luchevoi terapii zlokachestvennykh opukholei. Med. fizika. 2013. No. 3. P. 29-36.
12. Klepper L.Ya., Ushkova V.L., Myznikov A.V. Parizhskii metod planirovaniya kontaktnoi luchevoi terapii (KLT). Vtoroi Evraziiskii kongress po meditsinskoi fizike i inzhenerii «MEDITsINSKAYa FIZIKA-2005», 21-24 iyunya 2005 g. Sbornik materialov. Moscow. 2005.
13. Klepper L.Ya., Ushkova V.L. Optimal'naya i «Parizhskaya sistema» razmeshcheniya istochnikov v vnutritkanevoi luchevoi terapii zlokachestvennykh opukholei. Med. fizika. 2008. No. 3. P. 29-34.
14. Saati T. Tselochislennye metody optimizatsii i svyazannye s nimi ekstremal'nye problemy. Moscow: Mir. 1973. 213 p.
15. Klepper L.Ya., Antipina N.A. Opredelenie veroyatnosti izlecheniya opukholevogo zabolevaniya pri vnutritkanevoi luchevoi terapii zlokachestvennykh novoobrazovanii. Med. fizika. 2006. No. 4. P. 30-41.
16. «Bebig». Novye i usovershenstvovannye meditsinskie tekhnologii. Tekhnologiya vnutritkanevoi luchevoi terapii zakrytymi istochnikami I-125 lokalizovannogo raka predstatel'noi zhelezy. Brakhiterapiya». OOO «Bebig». 2006. 20 p.

For citation: Klepper LYa. Formation Optimum Doses Fields in Interstitial Radiotherapy as the Problem of the Covering of the Target by Circles of Identical Radius. Medical Radiology and Radiation Safety. 2015;60(1):54-61. Russian.

PDF (RUS) Full-text article (in Russian)

Medical Radiology and Radiation Safety. 2015. Vol. 60. No. 1. P. 39-44

RADIATION THERAPY

G.S. Zhamgaryan, L.I. Musabaeva, V.A. Lisin, Yu.I. Tyukalov

Combined Modality Treatment Including Intraoperative Electron and External Beam Radiation Therapies for Soft Tissue Sarcomas

Tomsk Cancer Research Institute, Tomsk, Russia, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

ABSTRACT

Purpose: To study the efficiency of the combined modality treatment including intraoperative radiation therapy (IORT) and external radiotherapy for patients with soft tissue sarcomas.

Material and methods: Between 1991 and 2011, a total of 115 patients with soft tissue sarcomas of the trunk and extremities received combined modality IORT and external beam radiation therapy. There were 44 (38 %), male and 71 female (62 %) patients aged from 15 to 75 years (median age 47.6 ± 2.5 years). Primary sarcomas were diagnosed in 79 (69 %) patients and recurrent sarcomas in 36 (31 %). The study included patients with locally advanced stage II-III soft tissue sarcomas and most of them (52 %) had stage III disease.

Results: Acute and late radiation-induced damages were observed only in patients who underwent surgery with 20 Gy IORT. No radiation-induced complications were found in groups I and II. In these groups of patients who received the total radiation dose of 60-65 Gy, the 2-year disease-free survival rates were 76.2 ± 7.5 % and 76.0 ± 11.3 %, respectively.

Key words: combined modality treatment, soft tissue sarcomas, intraoperative radiation therapy, external beam radiotherapy

REFERENCES

1. Lisin V.A. Otsenka predel'no dopustimoi odnokratnoi dozy pri intraoperatsionnoi luchevoi terapii. Med. fizika. 2006. No. 4. P. 18-23.
2. Lisin V.A., Kondrat"eva A.G. Osobennosti dozimetricheskogo planirovaniya intraoperatsionnoi luchevoi terapii pri ee sochetanii s distantsionnoi luchevoi terapiei. Med. fizika. 2013. No. 1. P. 9-14.
3. Lisin V.A. Raschet i analiz summarnogo raspredeleniya dozy elektronov i gamma-izlucheniya pri sochetanii intraoperatsionnoi luchevoi terapii s distantsionnoi gamma-terapiei. Med. fizika. 2012. No. 4. P. 36-42.
4. Tyukalov Yu.I. Intraoperatsionnaya luchevaya terapiya v kombinirovannom lechenii sarkom myagkikh tkanei: Avtoreferat diss. kand. med. nauk. Tomsk. 1998. 22 p.
5. Musabaeva L.I., Nechitailo M.N., Lisin V.A. Rezul'taty kombinirovannogo lecheniya s intraoperatsionnoi luchevoi terapiei i distantsionnoi gamma-terapiei zlokachestvennykh novoobrazovanii razlichnykh lokalizatsii. Medical Radiology and Radiation Safety. 2005. vol. 50. No. 2. P. 46-55.
6. Intraoperatsionnaya elektronnaya i distantsionnaya gamma-terapiya zlokachestvennykh novoobrazovanii. In Choinzonova  E.L. and Musabaevoi L.I. (eds.). Tomsk, NTL Publ. 2006. 216 p.

For citation: Galstyan IA, Nadejina NM, Levadnaya MG, Aksenenko AV. Ulcer-Cancer of the Skin as an Outcome of Local Radiation Injury. Medical Radiology and Radiation Safety. 2015;60(1):39-44. Russian.

PDF (RUS) Full-text article (in Russian)

Medical Radiology and Radiation Safety. 2015. Vol. 60. No. 1. P. 45-53

REVIEW

V.Y. Kovtun¹, V.D. Gladkih¹, Y.A. Davidovuch¹, E.S. Zhorova², V.V. Ogorodnikova¹, I.K. Belyaev², V.I. Krasnjuk²

Drug Formulation of the Ca-DTPA and Zn-DTPA

1. Federal State Establishment Science and Engineering Сenter «Pharmzashchita» FMBA of Russia, Khimki, Russia, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. ; 2. A.I. Burnasyan Federal Medical Biophysical Center of FMBA, Moscow, Russia

ABSTRACT

Purpose: To analyze modern approaches to using of therapeutic forms of DTPA (Ca-DTPA and a Zn-DTPA) for enhance the elimination of transuranium elements and decrease the dose formation of internal exposure.

Materials and methods: The content-analysis of publications related to development, pharmacokinetics and practical using of chelating compounds.

Results: Among the complexons used for prevention and treatment of radionuclide incorporation in the developed countries (the USA, the European community, Japan, China) for medical using allowed Ca-DTPA and Zn-DTPA as inhalations and injection solutions. In Russia Ca-DTPA only is allowed. The comparative characteristic of properties Ca-DTPA and Zn-DTPA testifies to basic uniformity of their biological effect. At the same time Zn-DTPA is characterized by less expressed toxicity and selectivity of action concerning nuclides. Hundreds of patients have been treated with Zn-DTPA; its efficiency, safety and smaller toxicity were shown. In Russia this compound isn’t allowed for medical use. It is necessary to make the maximum efforts for correction of such situation.

Conclusions: Considering features of biological effect of Ca-DTPA and Zn-DTPA the expedient scheme of treatment can be proposed: first Ca-DTPA, second Zn-DTPA. This scheme increases efficiency and reduces negative manifestations of prolonged using of Ca-DTPA in the monotherapy mode.

Key words: chelate, drug formulation, pentacinum, zinkacinum, internally deposited transuranic elements, drug for removing

REFERENCES

1. Schwarzenbach G., Kampitsch T., Steiner R., Komplexone I. Über die Salzbildung der Nitrilotriessigsäure. Helv. Chim. Acta. 1945. Vol. 28. No. 1. P. 828-840.
2. Schwarzenbach G., Kampitsch T., Steiner R. Komplexone II. Das Komplexbildungsvermögen von Iminodiessgsäure, Methyliminodiessgsäure, Aminomalonsäure und Aminomalonsäure-diessgsäure. Chim. Acta. 1945. Vol. 28. No. 1. P. 1133-1143.
3. Semenov D.I., Tregubenko I.P. Kompleksony v biologii i meditsine. Sverdlovsk, UNTs AN SSSR. 1984. 289 p.
4. Teoreticheskie osnovy i prakticheskoe primenenie. Transl. for German. Moscow, Goskhimizdat. 1958. 246 p.
5. Semenov D.I. Kompleksony v biologii i meditsine. Priroda. 1959. No. 8. P. 25-32.
6. Dyatlova N.M., Temkina V.Ya., Kolpakova I.D. Kompleksony. Moscow: Khimiya. 1970. 416 p.
7. Tikhonova L.I. Kompleksoobrazovanie tsirkoniya s nekotorymi poliaminopoliuksusnymi kislotami. Zh. neorg. khim. 1967. Vol. 12. No. 4. P. 939-943.
8. Razbitnaya L.M. Issledovaniya kompleksoobrazovaniya tseriya, ittriya i uranila s poliaminopoliuksusnymi kislotami. Avtoreferat dis. kand. khim. nauk. Moscow. 1964. 22 p.
9. Moskvin A.I. Issledovaniya kompleksoobrazovaniya Pu³⁺, Am³⁺, Cm³⁺ c nitrilotriuksusnoi i dietilentriaminpentauksusnoi kislotami. Radiokhimiya. 1971. Vol. 13. No. 4. P. 575-581.
10. Piskunov E.M., Rykov A.G. Issledovaniya kompleksoobrazovaniya s DTPA. Torii (IV). Radiokhimiya. 1972. Vol. 14. No. 2. P. 260-264.
11. Piskunov E.M., Rykov A.G. Issledovaniya kompleksoobrazovaniya s DTPA. Uran (IV). Radiokhimiya. 1972. Vol. 14. No. 2. P. 265-268.
12. Piskunov E.M., Rykov A.G. Issledovaniya kompleksoobrazovaniya s DTPA. Plutonii (IV). Radiokhimiya. 1972. 14. No. 2. P. 332-334.
13. Catsch A. Experimenteller Beitrage zur Frage der Bleidelkorporation durch Chelatbildner. Arzneim.-Forsch. 1967. Vol. 17. P. 493-495.
14. Chiadot P., Lafuma J. Toxicité aiguё des chelatants thérapeutiques utilisables dans l’industrie nucléaire. Rev. d’hygiene Med. Soc. 1962. Vol. 10. P. 391-401.
15. Planas-Bohne F., Ebel H. Dependence of DTPA-toxicity on the treatment schedule. Health Phys. 1975. Vol. 29. No. 1. P. 103-106.
16. Health physics in the People’s Republic of China. Health Phys. 1981. Vol. 41. No. 3. P. 585-588.
17. Volf V. Treatment of incorporated transuranum element. Techn. Rep. Series. No. 184. Vienna: IAEA. 1978, 168 p.
18. Seidel A. Metabolismus und Toxizität Therapeutischer Chelatbildner. Strahlentherapie. 1970. Vol. 139. No. 7. P. 603-610.
19. Doolan P.D., Schwartz S.L., Hayes I.R. et al. An evaluation of the nefrotoxicity of ethylenediaminetetraacetate and diethylentriaminetetraacetate in the rat. Appl. Pharmacol. 1967. Vol. 10. No. 3. P. 481-500.
20. Srot Z., Zylicz E., Zablotna R. et al. Badania porownawcze toksycznosci I effectywnosci chelatow kwasu dwuetylentrojaminopieiooctawego: Na₃CaDTPA, Na₃ZnDTPA i Na₃MnDTPA stosowanych do usuwania ⁴⁶Sc, ⁶⁵Zn i ¹⁴⁴Ce z organizmu szczura. Nucloonia. 1974. Vol. 19. No. 10. P. 917-931.
21. Taylor G.N., Williams J.L., Roberts H. et al. Increased toxicity of Na₃CaDTPA when given by protracted administration. Health Phys. 1974. Vol. 27. No. 3. P. 285-288.
22. Ebel H. Metabolismus und Toxizität therapeutischer Chelatbildner. Strahlentherapie. Vol. 149. No. 4. P. 450-456.
23. Taylor G.N., Mays Ch.W. Fetal injury induced by CaDTPA in dogs. Health Phys. 1978. Vol. 35. No. 6. P. 858-860.
24. Brummett E.S., Mays Ch.W. Teratological studies of ZnDTPA in mice. Health Phys. 1977. Vol. 33. No. 6. P. 624-626.
25. Calder S.E., Mays Ch.W., Taylor G.N., Brammer Th. Zn-DTPA safety in the mouse fetus. Health Phys. 1979. Vol. 36. No. 4. P. 524-526.
26. Mays Ch.W., Taylor G.N., Fischer D.R. Estimated toxicity of Ca-DTPA to the human fetus. Health Phys. 1976. Vol. 30. No. 2. P. 247-249.
27. Reuters T. Pentetate calcium Trisodium. Micromedex, Poisindex, Management. 2011. 21 p.
28. Seidel A., Volf V. Removal of internally deposited transuranium elements by Zn-DTPA. Health Phys. 1972. Vol. 22. No. 6. P. 779-783.
29. Taylor G.N., Lloyd R.D., Boseman J.J. et al. Removal of plutonium from beagles using Ca-DTPA and Zn-DTPA: Effects of initial DTPA injection. Health Phys. 1978. Vol. 35. No. 2. P. 201-210.
30. Carbaugh E.H., Lynch T.P., Cannon C.N. et al. Case study: three acute ²⁴¹Am inhalations with DTPA therapy. Health Phys., 2010. Vol. 99. No. 4. P. 539-546.
31. Akashi M., Tanosaki S., Kuroiwa N. et al. Effects of a chelating agent DTPA on excretion of heavy metal ions in healthy volunteers. In “IRPA 10, 10th Internat. Congress of the internat. Radiation Protection”. P-3a-194. 2000. Hiroshima.
32. Catsch A. Removal of transuranic elements by chelating agents. Facts, open questions and prospects. In “Diagnosis and Treatment of Incorporated Radionuclides”. Vienna: IAEA. 1976. P. 295-305.
33. Lineoln T.A. The use of DTPA and induced sputum as diagnostic techniques after internal contamination. In “Diagnosis and Treatment of Incorporated Radionuclides”. IAEA. 1976. P. 203-208.
34. Gasteva G.N., Krasnyuk V.I., Bad'in V.I. et al. Klinicheskaya otsenka perenosimosti i effektivnosti preparata «tsinkatsin» pri inkorporatsii plutoniya i ameritsiya v organizm cheloveka. Meditsina truda i prom. ekologiya. 2005. No. 3. P. 42-45.
35. Shchadilov A.E., Khokhryakov V.F., Kudryavtseva T.I. et al. Vliyanie pentatsina na uroven' ekskretsii plutoniya iz organizma cheloveka. Byull. sibir. med. 2005. Vol. 2. P. 128-132.
36. Grappin L., Berard Ph., Menetrier F. et al. Exposure to actinides: report on Ca-DTPA injections in CEA-AREVA centres. Radioprotection. 2007. Vol. 42. No. 2. P. 163-196.
37. Ohlenschlager L. Efficacy of Zn-DTPA in removing plutonium from the human body. Health Phys. 1976. Vol. 30. No. 2. P. 249-250.
38. Ohlenschlager L., Schieferdecker H., Smidt-Martin W. Efficacy of Zn-DTPA and Ca-DTPA in removing plutonium from the human body. Health Phys. 1978. Vol. 35. No. 5. P. 694-699.
39. Robinson B., Heid K.R., Aldridge T.H., Glenn R.D. 1976 Hanford Americium Exposure Incident: organ burden and radiation dose estimates. Health Phys. 1983. Vol. 45. No. 4. P. 911-921.
40. Lyubchanskii E.R. Primenenie Na₃Ca DTPA (pentatsina) dlya udaleniya Pu²³⁹ iz organizma krys pri ingalyatsionnom porazhenii. Medical Radiology and Radiation Safety. 1965. Vol. 10. No. 1. P. 45-49.
41. Lyubchanskii E.R. Primenenie Na₃Ca DTPA (pentatsina) dlya vyvedeniya Pu²³⁹ iz organizma krys pri ingalyatsionnom porazhenii. V kn. «Raspredelenie i biologicheskoe deistvie radioaktivnykh izotopov». Moscow: Atomizdat. 1966. P. 471-476.
42. Lyubchanskii E.R., Koshurnikova N.A. Profilakticheskoe primenenie aerozolei DTPA u krys pri khronicheskoi ingalyatsii Pu²³⁹. Med. radiol. 1968. Vol. 13. No. 10. P. 46-51.
43. Koshurnikova N.A., Lyubchanskii E.R. Vliyanie profilakticheskogo vdykhaniya pentatsina na otdalennye posledstviya ingalyatsii Pu²³⁹. Med. radiol. 1969. Vol. 14. No. 9. P. 29-34.
44. Dudley R.E, Muggenburg B.A., Cuddihy R.G. et al. Nasal absorption of DTPA in rats. Health Phys. 1980. Vol. 38. No. 5. P. 763-768.
45. Dudley R.E., Muggenburg B.A., Cuddihy R.G. et al. Absorption of DTPA from the respiratory tracts of beagle dogs. LF-60 (12-78). 1978. P. 195-199. (TsNII Atominform No. 517331).
46. Stather J.W., Smith H., Bailey M.R. et al. The retention of ¹⁴C-DTPA in human volunteers after inhalation or intravenous injection. Health Phys. 1983. Vol. 44. No. 1. P. 45-52.
47. Aronson A.L., Hammond P.B. Effect of two chelating agents on the distribution and excretion of lead. J. Pharm. Ther. 1964. Vol. 146. P. 241-251.
48. Bohne F., Harmuth-Hoene A.E., KÜrzinger K. et al. Metabolism und Toxizität therapeutischer Chelatbildner XII. Strahlentherapie. 1968. Vol. 136. No. 5. P. 609-616.
49. Bohne F., Harmuth-Hoene A.E., Weber K.M. Vergleichende Untersuchungen Über die Wirksamkeit von Chelatbildnern bei der Experimentellen Eisenpeicherkrankheit der Ratte. Naunyn-Schmiedebergs Arch. Pharmak. u. exp. Path. 1967. Vol. 257. P. 409-419.
50. Patent USA № 7914767. Oral DTPA for radionuclide chelation. 2011.
51. Reddy J.D., Cobb R.R., Dungan N.W. et al. Preclinical toxicology, pharmacology, and efficacy of a novel orally administered diethylenetriaminepentaacetic acid (DTPA) formulation. Drug Dev. Res. 2012. Vol. 73. No. 5. P. 232-242.
52. Hanker G.N., Weber W., Doyle-Eisele M. et al. Efficacy of a novel orally administered formulation DTPA tablets for decorporating an intravenously injected radionuclide: a comparison with intravenously administered licensed DTPA. Drug Dev. Res. 2012. Vol. 73. No. 5. P. 290-298.
53. Patent USA US RE No. 42748 E. Oral DTPA for radionuclide chelation.
54. Shankar G.N., Weber W., Doyle-Eisele M. et al. Improved decorporation of the actinide radioelement Am-241 with a novel orally available formulation of DTPA - efficacy and pharmacokinetic studies. In: ICRR2011, 14^th International Congress of Radiation Research. POS23-65. 2011. Warszawa.
55. Shankar G.N., Weber W., Doyle-Eisele M. et al. Efficacy of novel orally administered formulation of DTPA tablets for decorporating an intravenously injected radionuclide: a comparison with intravenously administered licensed DTPA. Drug Dev. Res. 2012. Vol. 73. No. 5. P. 290-298.
56. Shankar G.N., Potharaju S., Green C.N. Evaluating the toxicity of novel Zn-DTPA tablet formulation in dogs and rats. Drug Dev. Res. 2014. Vol. 75. No. 1. P. 37-46.
57. Pentetate calcium trisodium injection. Instruction for use. Available from: www.fda.gov/downloads/drugs/emergencypreparedness/bioterrorismanddrugpreparedness/USM131638.pdf. 2004.
58. Pentetate zinc trisodium injection. Instruction for use.Available from: www.fda.gov/downloads/drugs/emergencypreparedness/bioterrorismanddrugpreparedness/USM131639.pdf. 2004.
59. Calcium DTPA and Zinc DTPA drug products - submitting a new drug application. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. August 2004. Available from: http://www.fda.gov/cder/guidance/index.htm.
60. Decorporation of radionuclides from the human body. Eds. Henge-Napoli M.N., Stradling G.N., Taylor D.M. Radiat. Prot. Dosim. Special issue. 2000. Vol. 87. No. 1. EUR Report 19330.
61. Guidebook for the treatment of accidental internal radionuclide contamination of workers. Gerber G.B., Thomas R.S. Radiat. Prot. Dosim. 1992. Vol. 41. No. 1, 49 p.
62. Ohlenschlager L. Efficacy of Zn-DTPA in removing plutonium from the human body. Health Phys. 1976. Vol. 30. No. 2. P. 249-250.
63. Ohlenschlager L., Schieferdecker H., Smidt-Martin W. Efficacy of Zn-DTPA and Ca-DTPA in removing plutonium from the human body Health Phys. 1978. Vol. 35. No. 5. P. 694-699.
64. Robinson B., Heid K.R., Aldridge T.H., Glenn R.D. 1976 Hanford Americium Exposure Incident: organ burden and radiation dose estimates. Health Phys. 1983. Vol. 45. No. 4. P. 911-921.
65. Breitenstein B.D., Palmer H.E. Lifetime follow-up of the 1976 americium accident victum. Radiat.Prot.Dosim. 1989. Vol. 26. No. 1-4. P. 317-322.
66. Girand J.-M. Bilan de l’utilisation du DTPA au CEA et à la COGEMA. Electricite de France - Service de Radioprotection. Document No. 17, March 2001. 5 p.
67. Homeland security presidentaldirective. HSPD-18. Available from: http://www.fas.org/irp/offdocs/hspd-18.html. 2007.
68. Homeland security presidentaldirective. HSPD-21. Available from: http://www.fas.org/irp/offdocs/hspd-21.html. 2007.

For citation: Kovtun VY, Gladkih VD, Davidovuch YA, Zhorova ES, Ogorodnikova VV, Belyaev IK, Krasnjuk VI. Drug Formulation of the Ca-DTPA and Zn-DTPA. Medical Radiology and Radiation Safety. 2015;60(1):45-53. Russian.

PDF (RUS) Full-text article (in Russian)

Medical Radiology and Radiation Safety. 2015. Vol. 60. No. 1. P. 33-38

RADIATION THERAPY

O.P. Trofimova, O.I. Cheban, Z.P. Mikhina, S.V. Medvedev, Ju.I. Prjamikova, N.P. Schipilina, E.V. Timoshkina, E.V. Poddubskaya, A.A. Maklakova, N.V. Vekova, O.C. Zaichenko, A.V. Berdnik, Ju.V. Bikova, M.P. Baranova, I.P. Kovalenko, L.E. Rotobelskaya, S.I. Tkachev

Cardiovascular Complications in Patients with Breast Cancer After Breast-Conserving Treatment

N.N.Blokhin Russian Cancer research center, Moscow, Russia, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

ABSTRACT

Purpose: To evaluate the radiation dose on the heart in patients with left-sided localization of breast cancer receiving radiation therapy after breast-concerving treatment on the free breath and breath-hold at a deep breath.

Material and methods: The study included 113 patients with verified breast cancer T_1-2N_0-1M₀ st. with left-sided localization of tumors who were treated in the N.N. Blokhin Russian Cancer Research Center in 2012-2013. Patients were treated with radical organ resection followed by radiation therapy. Radiation therapy (RT) on the free breath was carried out in 53 patients and on breath-hold at deep breaths in 60 patients. RT - 5 times per week dose 2 Gy per day to a total dose of 50 Gy. Radiation dose distribution in under risk organs was assessed for clinical radiotherapy planning parameters V₂₅ Gy and D_mean to heart.

Results: The data presented show a significant reduction in the volume of the heart, which received a dose of 25 Gy - median performance V₂₅ in RT sync breathing in comparison with the free breathing below the 82 % and the average dose of heart-median performance below the 65 %. The difference is not reliable because of the small number of observations.

Conclusion: The RT with breath holding on deep inhalation in patients with left-sided breast cancer localization reduces an average dose to the heart and the heart volume at the dose of 25 Gy. This allows to expect a further reduction in the incidence of cardio-vascular complications.

Key words: radiotherapy, breast cancer, cardiovascular complications

REFERENCES

1. Kaprin A.D., Starinskii V.V., Petrova G.V. Zlokachestvennye novoobrazovaniya v Rossii v 2012 g. (zabolevaemost' i smertnost'). Moscow: FGBU «MNIOI im. P.A. Gertsena» Minzdrava Rossii. 2014. P. 10-12.
2. Gagliardi G., Constine L., Moiseeko V. Radiation dose-volume effects in the heart. Int. J. Radiat. Oncol. Biol. Phys. 2010. Vol. 76. No. 3. P. S77-S85.
3. Carver J.R., Shapiro Ch.L., Jacobs A. et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J. Clin. Oncol. 2007. Vol. 1. No. 25. P. 3991-4008.
4. Clarke M., Collins R., Darby S. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomized trials. Lancet, 2005. Vol. 366. No. 9503. P. 2087-2106.
5. Ridker P.M., Buring J.E., Rifai N. et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds score. J. Amer. Med. Assoc. 2007. Vol. 297. No. 6. P. 611-619.
6. Hooning M.J., Botma A., Aleman B.M. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J. Natl. Cancer Inst. 2007. Vol. 99. No. 5. P. 365-375.
7. Paszat L.F., Mackillop W.J., Groome P.A. Mortality from myocardial infarction following postmastectomy radiotherapy for breast cancer: A population-based study in Ontario, Canada. Int. J. Radiat. Oncol. Biol. Phys. 1999. Vol. 43. No. 2. P. 755-761.
8. Harris E.E., Correa C., Hwang W.T. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J. Clin. Oncol. 2006. Vol. 24. No. 25. P. 4100-4106.
9. Lipshultz S.E., Lipsitz S.R., Sallan S.E. et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J. Clin. Oncol. 2002. Vol. 20. No. 23. P. 4517-4522.
10. Swain S.M., Whaley F.S., Ewer M.S. et al. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer. 2003. Vol. 97. No. 11. P. 2869-2879.
11. Shapiro C.L., Hardenbergh P.H., Gelman R. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J. Clin. Oncol. 1998. Vol. 16. No. 11. P. 3493-3501.
12. Adams M.J., Hardenbergh P.H., Constine L.S. et al. Radiation-associated cardiovascular disease. Crit. Rev. Oncol. Hematol. 2003. Vol. 45. No. 1. P. 55-75.
13. Prosnitz R.G., Chen Y.H., Marks L.B. Cardiac toxicity following thoracic radiation. Semin. Oncol. 2005. Vol. 32. No. 2. P. S71-S80.
14. Wei X., Liu H.H., Tucker S.L. et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2008. Vol. 70. No. 3. P. 707-714.
15. Cuzick J., Stewart H., Rutqvist L. et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J. Clin. Oncol. 1994. Vol. 12. No. 3. P. 447-453.
16. Marks L.B., Yu X., Prosnitz R.G. et al. The incidence functional consequences of RT-associated cardiac perfusion defects. Int. J. Radiat. Oncol. Biol. Phys. 2005. Vol. 63. No. 1. P. 214-223.
17. Darby S.C., McGale P., Taylor C.W. et al. Long-term mortality from heart disease study of about 300 000 women in US SEER cancer registries. Lancet Oncol. 2005. Vol. 6. No. 8. P. 557-565.
18. Patt D.A., Goodwin J.S., Kuo Y.F. et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J. Clin. Oncol. 2005. Vol. 23. No. 30. P. 7475-7482.
19. Borger J.N., Hooning M.J., Boersma L.J. et al. Cardiotoxic effects of tangential breast irradiation in early breast patients: The role of irradiated heart volume. Int. J. Radiat. Oncol. Biol. Phys. 2007. Vol. 69. No. 4. P. 1131-1138.
20. Utehina O. Healthy tissue sparing postoperative radiotherapy for treatment of early stage breast cancer. Riga. Summary of the doctoral thesis. 2009. 32 p.

For citation: Trofimova OP, Cheban OI, Mikhina ZP, Medvedev SV, Prjamikova JuI, Schipilina NP, Timoshkina EV, Poddubskaya EV, Maklakova AA, Vekova NV, Zaichenko OC, Berdnik AV, Bikova JuV, Baranova MP, Kovalenko IP, Rotobelskaya LE, Tkachev SI. Cardiovascular Complications in Patients with Breast Cancer after Breast-Conserving Treatment. Medical Radiology and Radiation Safety. 2015;60(1):33-8. Russian.

PDF (RUS) Full-text article (in Russian)